Ipamorelin vs Tesamorelin
A side-by-side research comparison of Ipamorelin and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Ipamorelin | Tesamorelin |
|---|---|---|
| Full name | Ipamorelin (Selective GH Secretagogue) | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | FDA Approved |
| Mechanism | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 711.9 Da | 5,136 Da |
| Half-life | 2 hours | 26-38 minutes |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-300 mcg | 2 mg |
| Frequency | 1-3x daily | Once daily |
| Route | Subcutaneous injection | Subcutaneous injection |
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.